NCT07046013

Brief Summary

Assessment of relation between serum lactate dehydrogenase and immune thrombocytopenia

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for all trials

Timeline
14mo left

Started Aug 2025

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress40%
Aug 2025Jul 2027

First Submitted

Initial submission to the registry

June 14, 2025

Completed
17 days until next milestone

First Posted

Study publicly available on registry

July 1, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2025

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

July 1, 2025

Status Verified

June 1, 2025

Enrollment Period

1.8 years

First QC Date

June 14, 2025

Last Update Submit

June 22, 2025

Conditions

Immune Thrombocytopenia (ITP)

Outcome Measures

Primary Outcomes (1)

  • Relation between serum lactate dehydrogenase and immune thrombocytopenia

    About 2 years

Interventions

Lactate dehydrogenaseDIAGNOSTIC_TEST

It's elevation at the time of diagnosis

Eligibility Criteria

Age16 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Sample collected from people newly diagnosed Immune thrombocytopenia at the time of diagnosis. Laboratory investigations: LDH\_CBC\_ESR\_Bone marrow aspirate

You may qualify if:

  • Thrombocytopenia patients at the time of diagnosis.

You may not qualify if:

  • bone fractures \_ bone diseases\_ malignancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Purpura, Thrombocytopenic, Idiopathic

Condition Hierarchy (Ancestors)

Purpura, ThrombocytopenicPurpuraBlood Coagulation DisordersHematologic DiseasesHemic and Lymphatic DiseasesThrombotic MicroangiopathiesThrombocytopeniaBlood Platelet DisordersCytopeniaHemorrhagic DisordersAutoimmune DiseasesImmune System DiseasesHemorrhagePathologic ProcessesPathological Conditions, Signs and SymptomsSkin ManifestationsSigns and Symptoms

Central Study Contacts

Shaimaa Mahmoud Fahmy, Resident doctor

CONTACT

01149586292shaimaa333mahmoud333@gmail.com

Hassnaa Ahmed Abo elwafa, Prof.Dr

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

June 14, 2025

First Posted

July 1, 2025

Study Start

August 1, 2025

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

July 1, 2025

Record last verified: 2025-06